Novartis (NVS)
(Real Time Quote from BATS)
$101.89 USD
+1.68 (1.68%)
Updated May 10, 2024 01:28 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Brokerage Reports
Novartis AG [NVS]
Reports for Purchase
Showing records 461 - 475 ( 475 total )
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
New and Recent Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
New Drug Launch Weekly Retail Sales Tracker - Week Ended June 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Biotechnology/Biopharmaceuticals/BioDefense-New Drug Launch Weekly Retail Sales Tracker - Week Ending May 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Biotechnology/Biopharmaceuticals/BioDefense-New Drug Launch Weekly Retail Sales Tracker - Week ending February 22, 2013
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Griffin Securities Updates Coverage on Ligand Pharma. (LGND)
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Biotechnology / Biopharmaceuticals -Preview of Gout Abstracts at the Upcoming ACR
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Calendar of Events
Provider: WALL STREET ACCESS CORP.
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
RISK ARB TRADING UPDATE.
Provider: WALL STREET ACCESS CORP.
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
MERGERS & ACQUISITIONS
Provider: WALL STREET ACCESS CORP.
Company: Novartis AG
Industry: Medical - Drugs
Company: Novartis AG
Industry: Medical - Drugs
Novartis agrees to exercise its call option to buy remainder of Alcon''s shares
Provider: IIR GROUP
Analyst: KHAN F